Current Research on HIV Drug Resistance
HIV drug resistance is an unavoidable challenge for HIV/AIDS professionals, and it has long been a major obstacle hindering the global effort to contain HIV/AIDS. Pathogens journal launched a topical collection in 2021 on “Current Research on HIV Drug Resistance”, aiming to catch the latest advanc...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (152 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 02744nam-a2200793z--4500 | ||
|---|---|---|---|
| 001 | 993573564804498 | ||
| 005 | 20231214132852.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202212s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a 3-0365-5512-9 | ||
| 035 | |a (CKB)5470000001631600 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/94485 | ||
| 035 | |a (EXLCZ)995470000001631600 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Ji, Hezhao |4 edt | |
| 245 | 1 | 0 | |a Current Research on HIV Drug Resistance |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (152 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a HIV drug resistance is an unavoidable challenge for HIV/AIDS professionals, and it has long been a major obstacle hindering the global effort to contain HIV/AIDS. Pathogens journal launched a topical collection in 2021 on “Current Research on HIV Drug Resistance”, aiming to catch the latest advancements in HIV resistance diagnosis, surveillance and research. This book compiles all articles published in this collection, combining original research and review articles on HIV drug resistance. | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Epidemiology & medical statistics |2 bicssc | |
| 653 | |a HIV drug resistance | ||
| 653 | |a sanger sequencing | ||
| 653 | |a next-generation sequencing | ||
| 653 | |a interrupted antiretroviral therapy | ||
| 653 | |a HIV-1 | ||
| 653 | |a nef | ||
| 653 | |a Botswana | ||
| 653 | |a drug resistance mutations | ||
| 653 | |a 3'-polypurine tract | ||
| 653 | |a dolutegravir | ||
| 653 | |a single genome sequencing | ||
| 653 | |a drug resistance | ||
| 653 | |a integrase strand transfer inhibitors | ||
| 653 | |a replication fitness | ||
| 653 | |a case study | ||
| 653 | |a complex adaptive system | ||
| 653 | |a leverage points | ||
| 653 | |a systems mapping | ||
| 653 | |a Dar es Salaam | ||
| 653 | |a Tanzania | ||
| 653 | |a HIV | ||
| 653 | |a surveillance | ||
| 653 | |a public health | ||
| 653 | |a Mexico | ||
| 653 | |a HIV pretreatment drug resistance | ||
| 653 | |a HIV acquired drug resistance | ||
| 653 | |a Mexico City | ||
| 653 | |a antiviral therapy | ||
| 653 | |a protease inhibitor | ||
| 653 | |a protease | ||
| 653 | |a mutation | ||
| 653 | |a atazanavir | ||
| 653 | |a HCV | ||
| 653 | |a probe capture | ||
| 653 | |a enrichment | ||
| 653 | |a point-of-care test | ||
| 653 | |a resource-limited setting | ||
| 653 | |a testing | ||
| 653 | |a analytes | ||
| 653 | |a specimens | ||
| 653 | |a performance | ||
| 776 | |z 3-0365-5511-0 | ||
| 700 | 1 | |a Ji, Hezhao |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:34:53 Europe/Vienna |f system |c marc21 |a 2023-01-09 04:44:33 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5341789010004498&Force_direct=true |Z 5341789010004498 |b Available |8 5341789010004498 | ||